Table 1.
Demographic, laboratory and liver fibrosis characteristics
| Characteristics | Patients (n = 81) |
| Gender (male/female) | 40 (49.4%)/41 (50.6%) |
| Age (yr) - median (Q1;Q3) | 51 (30-78) |
| BMI (kg/m2) - median (Q1;Q3) | 26.5 (24.3-29.6) |
| ALT (IU/L) - median (Q1;Q3) | 50 (32.5-85) |
| AST (IU /L) - median (Q1;Q3) | 42 (28.5-61.5) |
| Platelet count (× 103/mm3) - median (Q1; Q3) | 202 (148-247) |
| Histological fibrosis stage, n (%) | |
| F0 | 5 (6.2) |
| F1 | 33 (40.7) |
| F2 | 20 (24.7) |
| F3 | 12 (14.8) |
| F4 | 11 (13.6) |
| TE (kPa) - median (Q1; Q3) | 6.9 (5-12.2) |
| TE success rate (mean ± SD) | 0.92 ± 0.21 |
| CAP (dB/m) - mMedian (Q1; Q3) | 237 (204-263) |
| ARFI (m/s) - median (Q1; Q3) | 1.25 (0.65-2.89) |
| APRI - median (Q1; Q3) | 0.66 (0.41-1.29) |
| FIB-4 - median (Q1; Q3) | 1.41 (0.90-2.45) |
BMI: Body mass index; ALT: Alanine amino transferase; AST: Aspartate amino transferase; TE: Transient elastography; CAP: Controlled attenuation parameter; ARFI: Acoustic radiation force impulse; APRI: Score index (AST/LSN AST/platelet); FIB-4: Score index (age × AST/platelet × ALT).